Wednesday, June 07, 2006

Just Approved in Canada --- ABBI

ABBI (Abraxis Bioscience, Inc.)

ABBI develops, manufactures, and markets injectable products for the treatment of cancer and various life-threatening diseases.

Today, Canada's health agency approved the company's Abraxane injection for the treatment of metastatic breast cancer. Abraxane is undergoing several other studies to determine its effectiveness against other cancers.

I expect its earning will grow stable even without some surprise result from the other studies.

It is a good pick for both short and long term investors.

Its closing price, as of 6/7/06, is $27.21.

My suggestion: Buy (8)


Post a Comment

<< Home